Researchers developed oral peptide derivatives from the mitochondrial protein VDAC1 that specifically increase testosterone in male rats while self-regulating through the HPG axis to prevent abuse potential.
4 oral peptides that robustly increase testosteroneFrom 11 active VDAC1-derived compounds, 4 synthetic peptides specifically and robustly increased androgen levels when given orally — with built-in self-regulation that prevents the supraphysiological levels associated with steroid abuse.
What the researchers found
The biologically active core of the VDAC1 cholesterol transport-enhancing peptide was identified as the tetrapeptide RVTQ. From this core, synthetic oral derivatives were designed, with 11 showing activity and 4 demonstrating robust, specific androgen increases. The lead compound RdVTQ was profiled across the lifespan of Brown-Norway rats and increased testosterone levels. The mechanism works within the HPG axis, meaning the body's natural feedback system self-regulates the response — preventing testosterone from rising to supraphysiological (abuse-potential) levels. Both subcutaneous and oral administration routes were effective.
Why it matters
Testosterone deficiency (hypogonadism) affects millions of men and currently requires injectable testosterone or topical gels, both of which bypass the body's natural regulatory system and carry risks of abuse and cardiovascular side effects. An oral peptide that works by enhancing the body's own testosterone production — with built-in self-regulation — could represent a fundamentally safer approach. The fact that it's a small peptide (4 amino acids) makes oral bioavailability achievable.
How the study worked
First, a subcutaneous delivery model for the parent peptide TV159-172 was established to study HPG axis interactions and identify the active core. The tetrapeptide RVTQ was identified as the minimal active sequence. Synthetic oral derivatives were designed and tested in a second animal model. Dose-response experiments identified the 4 most active compounds. The lead compound RdVTQ was profiled across the lifespan of Brown-Norway rats (a standard aging model). Circulating testosterone and related hormones were measured.
What this study cannot tell us
All experiments in rats — human translation is uncertain, particularly regarding oral bioavailability of peptides in human GI tract. The self-regulation claim via HPG axis needs verification in longer-term and higher-dose studies. The Brown-Norway rat is a specific aging model that may not represent all human testosterone deficiency patterns. Manufacturing and stability of small peptides for oral formulation need assessment. No safety/toxicology data beyond testosterone-specific endpoints were reported. The mechanism assumes VDAC1-mediated cholesterol transport is similarly rate-limiting in humans.
How to read the evidence
This is a preclinical drug development study with systematic identification of active peptides from a larger parent molecule, dose-response characterization, and lifespan profiling in rats. The methodology is thorough for the discovery stage, but all data are in rats and no human pharmacokinetic or safety data exist.
When this study was published
Published in 2022, this study describes a novel class of testosterone-boosting peptides that addresses a significant unmet clinical need — safer testosterone therapy. The field has continued to pursue peptide-based approaches to hormone modulation.
The bigger picture
Current testosterone replacement therapy replaces the hormone directly, shutting down the body's own production and bypassing natural regulation. This peptide approach is fundamentally different — it enhances the rate-limiting step of the body's own steroid hormone production. If translated to humans, it could provide a more physiological form of testosterone therapy that maintains the HPG feedback loop, potentially reducing the cardiovascular and fertility risks associated with current testosterone replacement.
Questions still open
- Will the RVTQ-derived peptides increase testosterone in humans with the same self-regulating safety profile seen in rats?
- Could these peptides treat age-related testosterone decline without the cardiovascular risks of current testosterone replacement therapy?
- Does the self-regulation truly prevent abuse, or could high-dose or frequent administration override the HPG feedback?
Common questions
Could there be a pill that safely boosts testosterone?
How is this different from anabolic steroids?
Read the original research
Oral administration of VDAC1-derived small molecule peptides increases circulating testosterone levels in male rats.
Frontiers in endocrinology, 13, 1003017
Citation
Martinez-Arguelles, Daniel B; Nedow, Jennifer W; Gukasyan, Hovhannes J; Papadopoulos, Vassilios. (2022). Oral administration of VDAC1-derived small molecule peptides increases circulating testosterone levels in male rats.. Frontiers in endocrinology, 13, 1003017. https://doi.org/10.3389/fendo.2022.1003017